Innovating Bacterial Vaccines at Scale
Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make protein antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
With this competitive advantage, VAX-24, Vaxcyte’s lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate being developed for the prevention of invasive pneumococcal disease (IPD) has the potential to be a best-in-class PCV in an already $7 billion global market that is poised to undergo significant growth. VAX-24 was recently granted FDA Breakthrough Therapy designation for the prevention of IPD in adults. Additionally, Vaxcyte’s pipeline includes VAX-31, a 31-valent PCV candidate, VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontitis, and VAX-GI, a novel prophylactic vaccine designed to prevent Shigella.
Stock Quote
Data Provided by Refinitiv. Minimum 15 minutes delayed.